Arrowstreet Capital’s Atea Pharmaceuticals AVIR Stock Holding History

Arrowstreet Capital’s Portfolio AVIR Stock Details AVIR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$979K	Hold	210,542	–	–	﹤0.01%	1646
2026 Q1	$1.13M	Buy	+210,542	New	+$967K	﹤0.01%	1530
2023 Q3	–	Sell	-101,587	Closed	-$380K	–	1249
2023 Q2	$380K	Buy	+101,587	New	+$380K	﹤0.01%	1090
2022 Q3	–	Sell	-10,878	Closed	-$77K	–	1264
2022 Q2	$77K	Buy	+10,878	New	+$74.3K	﹤0.01%	1195
2022 Q1	–	Sell	-102,775	Closed	-$919K	–	1190
2021 Q4	$919K	Sell	102,775 -75,780	-42%	-$1.18M	﹤0.01%	1175
2021 Q3	$6.26M	Buy	178,555 +47,695	+36%	+$1.32M	0.01%	880
2021 Q2	$2.81M	Buy	+130,860	New	+$3.93M	﹤0.01%	1246

Other funds holding AVIR

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

BCM

BML Capital Management Zionsville, Indiana $176M AUM 123.21% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Arrowstreet Capital's AVIR Position: Q2 2026 in Review

Arrowstreet Capital held its Atea Pharmaceuticals (AVIR) position steady in Q2 2026 at 210,542 shares worth $979K. The position accounts for ﹤0.01% of the portfolio, ranked #1646.

Arrowstreet Capital first reported a position in AVIR in Q2 2021 and has held it in 7 quarters since. The position peaked at $6.26M in Q3 2021. 124 funds tracked by Wall St. Rank hold AVIR as of Q2 2026.

Arrowstreet Capital held 210,542 shares of Atea Pharmaceuticals worth $979K as of Q2 2026.
Arrowstreet Capital left its Atea Pharmaceuticals share count unchanged in Q2 2026.
Atea Pharmaceuticals made up ﹤0.01% of Arrowstreet Capital's portfolio in Q2 2026, its #1646 holding.
Arrowstreet Capital first reported a position in Atea Pharmaceuticals in Q2 2021 and has held it in 7 quarters since.
Arrowstreet Capital's Atea Pharmaceuticals position peaked at $6.26M in Q3 2021.
124 funds tracked by Wall St. Rank held Atea Pharmaceuticals as of Q2 2026.

Based on Arrowstreet Capital's 13F filing for Q2 2026, filed 13 Aug 2026.